NEW YORK, Sept. 28 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical company with operations in the U.S. and China, today announced that Alan G. Harris, MD, PhD, the Company’s Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs, will participate in a panel discussion titled “Advantages and Challenges of Corporate-Academic Collaborations”. The panel discussion will take place between 2:00pm - 3:00pm in the Thomson Room during the 4th Annual New Jersey Stem Cell Research Symposium being held at the Bridgewater Marriott in Bridgewater, NJ on Wednesday, September 29, 2010.
The panel discussion will be chaired by Dr. Martin Grumet, Professor in the Department of Cell Biology & Neuroscience and Director of Rutgers Stem Cell Research Center at Rutgers University. Other panelists include Dr. Joachim Kohn, member of the Board of Governors, Professor of Chemistry and Chemical Biology, and Director of New Jersey Center for Biomaterials at Rutgers University as well as Dr. Rodney Turner, Senior Director of Corporate Business Development of Life Technologies. This panel of academic and corporate scientists will discuss their experiences, goals, and recommendations for scientists wishing to establish collaborative projects across traditional boundaries.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact | |
Robin Smith | |
NeoStem, Inc. | |
Phone: +1 (212) 584-4174 | |
E-mail: rsmith@neostem.com | |
SOURCE NeoStem, Inc.
